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Cell wall architecture
The cell wall of the major fungal pathogen Candida albicans consists of an outer layer that is
made up of highly mannosylated proteins. The proteins are attached to the inner layer of the
cell wall and appear perpendicular to the cell surface forming a fibrillar protein coat (Fig 1A).
The polysaccharide rich inner layer is mainly made up of β-1,6- and β-1,3-glucans and chitin
while β-1,3-glucans and chitin are the structural polysaccharides in the cell wall.
The development of antifungal therapies that target the cell wall has received great attention
(Fig 1A) but with only limited success. The only cell wall-targeting antifungal agents, licenced
for human infections, are echinocandins.
Which cell wall polysaccharide is the most attractive antifungal target?
Chitin
Chitin is a linear homopolymer of β-1,4-linked N-acetylglucosamine (GlcNAc) and is essential
for cell viability. Chitin is synthesised by a family of membrane-localised chitin synthase
enzymes (Chs1 to 3, and Chs8 in C. albicans) and Chs1 is essential [1]. Polyoxins and nikko-
mycins are potent inhibitors of Chs enzyme that compete with Chs substrate UDP-GlcNAc for
Chs binding, due to their structural similarity but have limited effects on whole cells. Nikko-
mycin Z is effective against Coccidioides species causing respiratory infections. The drug
reduced the fungal pulmonary burdens by 6-log40 2 days post infection, but clinical trials were
terminated due to lack of finance [1,2].
The enzymes involved in chitin synthesis have specialised functions but can be functionally
redundant under specific conditions. In addition, subtle differences in protein structure
between Chs family members has complicated the development of efficient chitin synthase
inhibitors. For example, a Chs1-specific inhibitor, RO-09-3143, blocked septum formation by
Chs1 and arrested cell growth, but inhibition of Chs1 was only lethal in chs2Δ deletion mutant
suggesting functional redundancy [3]. Other chitin synthase inhibitors such as the 3-substi-
tuted amino-4-hydroxycoumarin derivatives have also been found to have antifungal activity
[4], but none has made it to the clinic.
β-1,3-glucan
β-1,3-glucan is a polymer of glucose units and can exist in a stable triple helical structure
which gives it some degree of elasticity and tensile strength making it the main structural poly-
saccharide in the cell wall of most fungi [5]. β-1,3-glucan has been the most attractive antifun-
gal target due to its central structural role in the cell wall. β-1,3-glucan is synthesised by
essential β-1,3-glucan synthase enzymes composed of an integral membrane protein catalytic
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subunit, Fks, and a regulatory subunit, Rho1 (Fig 1A). The echinocandins (caspofungin, mica-
fungin, and anidulafungin) are a class of antifungal agents that noncompetitively inhibit β-
1,3-glucan synthesis through inhibiting Fks [6]. They are fungicidal against Candida species
[7]. Resistance to the echinocandins in Candida species is due to FKS1 hotspot mutations, and
tolerance occurs due to cell wall remodelling and compensatory up-regulation of chitin syn-
thesis. Recently, other β-1,3-glucan inhibitors such as enfumifungin have been identified. The
lead molecule SCY-078 (ibrexafungerp) is an orally active synthetic derivative of enfumifungin
with in vitro antifungal activity. In vivo, ibrexafungerp is extensively distributed in the tissue
and is active against Candida and Aspergillus species [8]. Drug resistance to ibrexafungerp was
mapped to FKS1, although strains resistant to the echinocandins do not display cross-resis-
tance to ibrexafungerp, thus emphasising different mechanisms of action for both agents [9–
12]. A Phase I clinical trial of the drug showed mild-to-moderate inflammation-related
Fig 1. A model illustrating cell wall architecture and antifungal agents targeting specific components of the cell
wall (A). Several antifungal agents are available that target the cell wall, but only the echinocandins have been licenced
for the treatment of fungal infections; research into β-1,6-glucan inhibitor has been relatively unsuccessful. Cell wall
integrity pathway leading to caspofungin drug tolerance (B). The Pkc pathway is activated in response to damage to
the cell wall caused by inhibition of β-1,3-glucan synthesis by echinocandins. The signal that cell wall is weakened is
transduced by membrane-bound mechanosensors such as members of the Wsc family, to activate Rho1. Rho1 activates
Pkc1 which in turn activates the downstream MAP kinase cascade leading to the phosphorylation of Mkc1. A number
of transcription factors are then activated including Cas5 and Rlm1 that switch on the expression of genes involved in
cell wall construction and remodelling. The calcium signalling pathway is involved in cell wall salvage response. The
pathway is activated by Ca2+ that enters the cell through membrane-localised channels or is released from intracellular
stores. Ca2+ binds to and activates calmodulin (Cmd1). Cmd1 activates the phosphatase calcineurin, which is made up
of 2 subunits Cna1 and Cnb1. Calcineurin dephosphorylates the transcription factor Crz1. Crz1 then moves into the
nucleus and induces the expression of genes through binding to CDREs within their promoter sequences. The calcium
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thrombotic events in healthy volunteers; oral and intravenous formulations set for Phase II
clinical trial in the third quarter of 2018 have been completed, while a Phase III clinical trial to
evaluate the efficacy of oral ibrexafungerp on recurrent vulvovaginal candidiasis is ongoing
and estimated to be completed in September 2021.
Other β-1,3-glucan synthesis inhibitors under development include rezafungin (CD101), a
novel echinocandin [13], and piperazinyl-pyridazinone [14]. Rezafungin is a structural ana-
logue of anidulafungin with in vivo activity against Candida and Aspergillus species. Rezafun-
gin is currently in Phase III clinical trial. The piperazinyl-pyridazinones have in vitro activity
against Candida and Aspergillus species as well as other fungi and have potency in vivo against
Candida glabrata. Piperazinyl-pyridazinone is effective against echinocandin-resistant C. albi-
cans probably because it binds to a different region of Fks1 from echinocandins [14]. Signifi-
cant success has been seen in developing β-1,3-glucan synthesis inhibitors partly because β-
1,3-glucan is synthesised by a single synthase.
β-1,6-glucan
β-1,6-glucan plays a central role in cell wall organisation and structure by linking cell wall pro-
teins (CWPs) to the cell wall matrix [15]. Several genes such as KRE9, KRE6, and KRE5 have
been associated with β-1,6-glucan synthesis in S. cerevisiae and C. albicans [16]. The synthesis
of β-1,6-glucan has been proposed as a promising drug target strengthened by the fact that
CaKre9 is essential. The unavailability of a specific protein whose catalytic activity is directly
linked to the synthesis of β-1,6-glucan has made the development of inhibitors difficult despite
its importance in cell wall organisation. Pyridobenzimidazole derivative, D75-4590 was found
to target and inhibit Kre6. C. albicans cells treated with D75-4590 had reduced level of β-
1,6-glucan. Other derivatives of pyridobenzimidazole, such as D21-6076, have in vitro and in
vivo activities against C. albicans and C. glabrata. Synergistic effect has been detected in the
interaction of a β-1,6-glucan inhibitor, D11-2040, and caspofungin against C. albicans [17].
Are cell wall mannoproteins better antifungal targets than cell wall
polysaccharides?
The cell wall mannoproteins are made up of several classes; 88% are glycosylphosphatidylinosi-
tol (GPI)-modified proteins. GPI-modified mannoproteins are involved in cell wall synthesis,
organisation and remodelling, and virulence. These include proteins with glycosylhydrolase,
glycosyltransferase, or transglycosidase activities such as Crh and Phr families that function in
the extracellular space to modify, assemble, and crosslink the essential cell wall polymers
extruded into the wall space. These enzymes are excellent antifungal targets that act down-
stream of cell wall salvage pathways and inhibiting their synthesis and localisation to the cell
wall could impact on virulence and cell wall biosynthesis significantly. Molecules have been
identified which can interfere with the posttranslational modification of cell wall mannopro-
teins: glycosylation and the synthesis and attachment of the GPI anchor. One is a pyridine-
2-amine-based molecule, APX001A, which inhibits the acylation of the inositol ring during
GPI anchor synthesis, a step catalysed by Gwt1, an inositol acyltransferase. Deletion of GWT1
is lethal, or leads to temperature sensitivity and slow growth, depending on strain genetic back-
ground. APX001A is effective at low concentrations against Candida, Aspergillus, Fusarium,
and Scedosporium species. It is also effective against caspofungin-resistant C. albicans.
APX001A had elevated in vitro and in vivo activities against Candida auris compared to anidu-
lafungin. Phenoxyacetanilide (gepinacin) can also inhibit Gwt1 and has antifungal activity
against diverse yeasts and moulds [18]. M720 is an inhibitor of phosphoethanolamine transfer-
ase-I, Mcd4, involved in the GPI anchor synthetic pathway with in vivo activity against C.
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albicans [19]. APX001A and M720 have synergistic effect against C. albicans [19]. Other
enzymes involved in the GPI anchor synthesis such as Smp3 have also been proposed as thera-
peutic targets [20,21]. Rhodamine-3-acetic acid derivatives such as OGT2468 inhibit cell wall
mannoprotein synthesis by inhibiting protein glycosylation [22].
Cell wall mannoproteins as potential drug and vaccine targets present a new opportunity to
combat fungi infection, though it has gained relatively less attention/success compared to the
development of antifungal agents that target β-1,3-glucan synthesis.
Are cell wall localised virulence factors promising targets for
vaccine and immunotherapy development?
There are no licenced vaccines for fungal diseases and most individuals who suffer from systemic
mycoses have impaired immunity that makes them susceptible to invasive infections. With
impaired immunity, it would be difficult for immune-based therapies to eradicate the infection.
This limited effectiveness of antifungal drugs could be improved by developing antibody therapies.
The fungal cell wall glycoproteins are involved in adhesion to surfaces, medical devices, and host
cells. GPI-modified proteins are required for morphogenesis, virulence, and resistance to macro-
phages, making them potential candidates for vaccine and immunotherapy development [23].
The main group of adhesins in C. albicans is the family of 8 agglutinin-like sequence (Als)
surface glycoproteins encoded by the ALS genes. The Als proteins are potent virulence factors
and the recombinant N termini of Als1 and Als3 have been shown to have potential as prophy-
lactics. The rAls1-N vaccine was found to protect mice against oropharyngeal and dissemi-
nated candidiasis. The rAls3-N vaccine protects mice against C. albicans infections by
stimulating Th1/Th17 lymphocytes to produce high levels of IFN-γ and IL-17A as well as che-
mokines. These cytokines enhance the capacity of phagocytes to kill the pathogen. The vaccine
has been shown to confer protection to immunocompetent mice from systemic, oropharyn-
geal, and vaginal candidiasis. Human trials with the rAls3-N vaccine are ongoing [24], and
data show that the vaccine is safe and induce rapid and robust immune response [25].
Hwp1 and Hyr1 are outer surface mannoproteins found on germ tubes and hyphal cells of
C. albicans. Recombinant Hyr1 vaccine has been found to protect mice against haematogen-
ously disseminated candidiasis. Anti-rHyr1 antibodies neutralise Hyr1 antigenic effect in vitro
and in vivo [26]. Hwp1 has been used in a synthetic glycopeptide vaccine construct, combining
β mannan and a peptide epitope, which was found to protect mice against disseminated candi-
diasis. These vaccine candidates are promising and may gain clinical approval soon.
C. albicans uses receptor proteins such as Rbt5 on the cell surface to take up nutrients such
as iron during infection. Monoclonal antibody C7 was thought to exert candidacidal activity
by blocking the iron uptake pathway in C. albicans, though this effect is reversible by adding
iron to the growth medium [27].
Inhibiting or blocking these cell surface virulence factors may be useful in reducing the
progress of fungal infections especially with drug-resistant strains. However, the abundance
and redundancy as well as compensatory activities in the function of these proteins have stalled
rapid development of drugs/vaccines/immunotherapies. Thorough investigation of each cell
surface protein may broaden the available protein candidates for the development of prophy-
lactics, immunotherapies, and therapeutics.
How do cell wall compensatory mechanisms that lead to cell wall
remodelling impact on antifungal efficacy?
Echinocandins are used as a first-line drug against invasive candidiasis. Resistance to echino-
candins has developed through acquisition of point mutations in FKS1 or its paralogues. These
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point mutations are clustered around 2 hotspots mapped to amino acids at positions 641 to
649 (hotspot 1) and 1,345 to 1,365 (hotspot 2). Point mutations that alter echinocandin sensi-
tivity decrease enzyme velocity, Vmax, but not the binding affinity, Km, of the drug for Fks
enzyme. Serine is frequently substituted with phenylalanine, proline, or tyrosine at position
645. These mutations confer resistance as homozygous and heterozygous alleles to all 3 echino-
candins. However, not all FKS1 mutations are associated with reduced susceptibility to the
echinocandins [28]. Recently, the SENTRY surveillance project has examined the prevalence
of FKS1 mutations in echinocandin-resistant isolates and found that the majority of resistant
isolates of the major pathogenic Candida species tested do not harbour these mutations [29]
suggesting that alternative mechanisms including cell wall remodelling (Fig 1B) may contrib-
ute to drug resistance. β-1,3-glucan and chitin, the 2 cell wall structural polymers reinforce
and complement each other in a dynamic process mediated by wall glycoproteins to maintain
an intact cell wall. Cell wall remodelling alters the susceptibility of C. albicans and Aspergillus
fumigatus to echinocandin drugs. In vitro treatment of C. albicans with subinhibitory concen-
trations of caspofungin induces increased chitin synthesis as a compensatory response,
through activation of the Pkc, calcineurin (Fig 1B), and HOG signalling pathways. Activation
of the cell wall damage pathway leads to cell wall/chitin remodelling resulting in a thicker wall
with increased chitin content. C. albicans cells with elevated chitin content in the wall are less
susceptible to caspofungin treatment in vitro and in vivo [30]. The observed elevation in cell
wall chitin content appears to be an adaptive mechanism to maintain an intact cell wall and
not a genetic alteration but remodelling of the cell wall may give the fungus a window of
opportunity to acquire the point mutations that subsequently fix echinocandin resistance in
the population. Some C. albicans-resistant clinical isolates have been found to have hotspot
mutations in addition to a thicker wall with elevated wall chitin content [31,32]. This has led to
the proposal that combination therapies that block both glucan and chitin synthesis may be
attractive to abrogate the acquisition of caspofungin tolerance and resistance.
The CWI pathway and activation of chitin synthesis must be overcome in order to reduce
the resistance to and increase the effectiveness of β-1,3-glucan-targeted therapies. Several new
β-1,3-glucan synthase inhibitors have been discovered. If they are clinically approved, they
may share the same fate as the echinocandins, activating compensatory cell wall remodelling
activities when used at suboptimal concentrations or due to reduced bioavailability in some
host niches. Thus, a clinically approved agent that directly and noncompetitively inhibits the
synthesis of chitin may improve the clinical usefulness of β-1,3-glucan inhibitors in terms of
spectrum of activity and effectiveness.
The cell wall remains one of the most attractive antifungal targets yet it is a virtually an
unexploited area of research compared to the bacterial cell wall in terms of clinically approved
wall-targeting drugs. Even with recent successes in understanding cell wall biogenesis, more
research is needed if more effective antifungal therapies are to earn clinical approval.
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